![](https://www.udayavani.com/wp-content/uploads/2025/02/net-India-pti-fiel-415x233.png)
![](https://www.udayavani.com/wp-content/uploads/2025/02/net-India-pti-fiel-415x233.png)
Team Udayavani, May 26, 2020, 9:43 AM IST
The World Health Organization said that it will briefly drop hydroxychloroquine—the anti-malaria drug from its study into trial COVID-19 medicines on Monday, May 26.
In a press briefing, the WHO chief general Tedros Adhanom Ghebreyesus said that a paper published last week in the Lancet demonstrated that individuals taking hydroxychloroquine were at a higher danger of death and heart issues. Considering that the WHO will temporarily pause the worldwide clinical trial of hydroxychloroquine for COVID-19 treatment.
Tedros stated that hydroxychloroquine and chloroquine are approved medicines for treating Malaria or autoimmune diseases.
“The other medicines in the trial will continue to be tested including the experimental drug remdesivir, and HIV combination therapy,” he added.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
$21 mn for ‘voter turnout in India’: Elon Musk-led DOGE cuts grant
Nepal Deputy PM Paudel sustains burn injuries while inaugurating Pokhara Tourism fair
Britain’s Railway celebrates 200 years in Bollywood style with ‘DDLJ’ musical
India not neutral; it is on side of peace: PM Modi on Russia-Ukraine conflict
Iranian travel agency operator ordered to leave Singapore for facilitating visas for terrorism-linked individuals
India Nets: Shami works on lengths with Morkel, Pant recovers after freak hit by Hardik shot
To ban or not to ban? Countries debate regulations on smartphone usage in schools
PM didn’t tell his good friend about country’s outrage over handcuffing Indian deportees: Congress
Maha Kumbh: Akhilesh seeks compensation to kin of devotees killed in accidents
“Namma Sante” buzz: From coconut shell art to pure honey delights!
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.